Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination
Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.
Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.
Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.
The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.